{'fraction_non_alphanumeric': 0.03133640552995392, 'fraction_numerical': 0.0, 'mean_word_length': 5.961538461538462, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
[Managing cutaneous toxicities of targeted therapies].

Molecularly targeted therapies have shown efficacy in many types of cancer, and the induction for their use is increasing rapidly. However, it is frequently associated with varied and unique cutaneous side effects, such as hand-foot-syndrome, rash, dry skin and paronychia. These effects, when severe or mild, tend to terminate the therapy because they inevitably impact the quality of life of patients. Treatment by emollients(steroids and moisturizing creams), topical antibiotics(MINO), topical corticosteroids, and antihistamines are accurately required at the early stages. Close interaction, among prescribers, dermatologists and nurses, is highly recommended in order to introduce preventative skin care(homeostasis)based on moisture retention, clean skin, and protection from agents. The side effects can be diagnosed and treated early by the multidisciplinary team. The balances between therapeutic benefit and cutaneous reaction should be considered, thus allowing for potentially greater success of anticancer therapy.